Clin2
NCT05534360Possibly a fitNot yet recruiting

Tenecteplase treatment registry for acute ischemic stroke

Stroke, Acute

Part of Brain & nervous system, Heart & circulation clinical trials.

This registry looks at how people with an acute ischemic stroke (a blocked artery) are treated when they receive tenecteplase through a vein. It may help doctors understand outcomes and care for different stroke timing situations.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
5,000 people
Ages
18 years and older
Study type
Observational

Who can take part

  • You are 18 years or older.
  • You have had an acute blocked-artery stroke confirmed on a CT or MRI scan.
  • The stroke symptoms started within 270 minutes, or your stroke was found by special scan criteria (like wake-up stroke).
  • You received tenecteplase through an IV (a medicine given through a vein).
  • Your doctors said you can safely receive IV clot-busting medicine.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06320431Recruiting· Phase 3
Clot-busting drug for disabling stroke within 4.5 hours

This trial tests a clot-busting drug called tenecteplase for people having a disabling ischemic stroke (a clot blocking blood flow to the brain). It aims to see if the drug can help improve recovery when given within 4.5 hours of symptoms starting.

Sydney, Barangaroo
NCT07536165Not yet recruiting
Late-window IV tenecteplase for acute ischemic stroke

This registry tracks how well tenecteplase (a clot-busting medication) works when given more than 4.5 hours after a stroke starts. Researchers want to learn if treating strokes this late can still help patients recover.

Guangzhou, Guangdong
NCT06904911Recruiting· Phase 2
Study of tenecteplase into the artery after clot removal for stroke

This study tests a clot-dissolving drug called tenecteplase given directly into the artery after a mechanical thrombectomy (clot removal). The goal is to see if it helps improve blood flow to the small vessels in the brain after the main clot is removed.

Philadelphia, Pennsylvania
NCT07469293Not yet recruiting· Phase 3
Study of artery-injected tenecteplase for stroke with medium vessel blockage

This trial tests a clot-busting drug called tenecteplase, given directly into the blocked artery, for people who have had a stroke caused by a medium-sized brain vessel blockage within the last 24 hours. It aims to see if this treatment is safe and effective in improving recovery.

Baise City, Guangxi
NCT07357987Recruiting· Phase 3
Stroke treatment with tenecteplase via artery

This trial tests a clot-busting drug called tenecteplase given directly into the brain artery for people having a moderate stroke caused by a blockage in a medium-sized blood vessel. The goal is to see if it helps improve recovery when given within 24 hours of stroke symptoms starting.

Beijing, Beijing Municipality
NCT07361302Recruiting· Phase 3
Tenecteplase for stroke after 4.5 hours

This trial tests a clot-dissolving medicine called tenecteplase for people who had a stroke more than 4.5 hours ago. It may help you recover if given later than usual.

Buenos Aires

Hear when a new Stroke, Acute trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.